Table 4.

Glycosylation gene SNPs significantly associated with ovarian cancer risk among African American subjects

GeneSNPCase/control (100/96)MAF*PModelOR (95% CI)P§
FUT5rs8108862CCCTTT
67/4929/422/10.200.01D0.47 (0.22-1.00)0.049
FUT9rs1325078GGGCCC
23/3153/4524/200.470.62D2.29 (1.06-4.95)0.032
GALNT1rs6507133TTTAAA
47/4641/4112/80.310.79A1.88 (1.09-3.25)0.021
rs11663626TTTCCC
47/4641/3912/80.310.95A1.95 (1.12-3.41)0.016
MGAT5rs1257189GGGAAA
28/2945/4927/180.470.74R2.81 (1.16-6.80)0.020
rs1257196GGGAAA
39/2941/4820/180.420.81R2.26 (1.02-4.98)0.040
ST3GAL3rs3011217CCCTTT
50/3941/459/120.330.86A2.12 (1.21-3.71)0.0068
ST8SIA2rs3759917TTTGGG
30/2048/4622/300.500.76A0.56 (0.33-0.93)0.022
ST8SIA5rs3889927CCCTTT
66/5428/356/70.230.69A0.54 (0.30-0.98)0.039
rs3897629AAATTT
46/4542/4711/40.310.05A1.90 (1.02-3.52)0.037
  • * MAF estimated using both cases and controls.

  • P for testing departure from HWE among controls.

  • Genetic models (A, additive; D, dominant; R, recessive) with adjustment for age, geographic region, BMI, HRT use, oral contraceptive use, and parity/age at first birth.

  • § P for testing the genetic effects before multiplicity adjustment.